GlassScriptPhysician profile
Christopher Michael Douglas
NPI 1770041485
$1,765.76
in general payments reported to CMS, 2019-2025
31 companies · $421 in 2025
The $421 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $754 · 2022: $165 · 2023: $199 · 2024: $226 · 2025: $421.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $778 · Education: $68.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $778.37 |
| Education | $68.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Progenics Pharmaceuticals, INC. | $239.00 | 2022-2023 | Pylarify |
| Dendreon Pharmaceuticals LLC | $218.73 | 2022-2024 | Provenge |
| Amgen INC. | $138.04 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $125.00 | 2021 | |
| Viiv Healthcare Company | $118.99 | 2025 | Apretude |
| Astellas Pharma US INC | $104.99 | 2021-2023 | Veozah |
| Procept Biorobotics Corporation | $101.54 | 2025 | |
| Teleflex LLC | $78.64 | 2025 | Barrigel |
| 180 Medical, INC. | $72.14 | 2023-2024 | |
| Janssen Biotech, INC. | $68.00 | 2025 | Erleada |
| Abbvie INC. | $45.74 | 2021 | |
| Novo Nordisk INC | $43.31 | 2021 | |
| Janssen Pharmaceuticals, INC | $40.23 | 2021 | |
| Pfizer INC. | $37.35 | 2021-2025 | |
| Urogen Pharma, INC. | $34.62 | 2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $32.06 | 2021 | |
| Myovant Sciences INC. | $27.65 | 2021 | |
| Eisai INC. | $26.82 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $25.47 | 2021 | |
| Medtronic, INC. | $24.73 | 2023 | Interstim |
| Teva Pharmaceuticals USA, INC. | $22.60 | 2021 | |
| Amarin Pharma, INC. | $19.00 | 2021 | |
| Bausch Health US, LLC | $17.58 | 2021 | |
| Lilly USA, LLC | $15.07 | 2021 | |
| Sumitomo Pharma America, INC. | $14.52 | 2023 | Orgovyx |
| Tolmar Pharmaceuticals, INC. | $14.52 | 2021 | |
| Boston Scientific Corporation | $14.09 | 2021 | |
| Glaxosmithkline, LLC. | $11.71 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $11.30 | 2021 | |
| Allergan, INC. | $11.26 | 2021 | |
| Antares Pharma, INC. | $11.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Douglas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.